
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is a global leader in the healthcare industry, with a diverse portfolio of products focused on cardiovascular and diabetes devices, nutritional products, and diagnostic equipment. The company's recent FDA approval for its TactiFlex Duo product, along with its strong pipeline and market-leading position in high-growth areas, position it well for continued success in the future. While there are risks associated with the competitive landscape and potential delays in product launches, Abbott's strong financials and focus on high-growth areas make it a positive investment opportunity.
Bears say
Abbott Laboratories is facing several challenges in its different business segments including pricing pressure in its global nutrition business, pricing and procedure volume pressure in its medical devices unit, and regulatory timing for product approvals. The company also faces risks associated with predicting demand for product launches in emerging markets. Despite positive data from its FlexPulse IDE study, the outlook for its Medical Devices and Diagnostics segment remains uncertain. While the company has demonstrated strong performance in its U.S. cardiology business and expects a recovery in its nutrition business, there are still risks involved in achieving its projected acceleration in the second half of the year. Additionally, potential risks such as healthcare policy changes, competition, and government regulations could impact the company's financials and future growth.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares